Machine similar to dialysis removes cholesterol from blood

Some patients are genetically prone to such dangerously high levels of cholesterol that no amount of diet, exercise and medications can reduce their cholesterol to safe levels.

So Loyola University Medical Center is offering a treatment called LDL apheresis, which is similar to . Once every two weeks, a patient spends two to four hours connected to an apheresis unit that removes 70-to-80 percent of the patient's LDL (bad) cholesterol, then returns the blood to the body. The good is not removed.

Loyola is among a handful of centers in the Midwest – and the only academic medical center in Chicago—to offer LDL apheresis.

The Loyola LDL Apheresis Program is intended for patients who have been unable to control cholesterol with and medications. They include patients with who have LDL cholesterol greater than 200 mg/dL, and patients without who have LDL levels greater than 300 mg/dL.

About 1 in 500 people have that cause three to five times as high as normal levels. The condition, called familial hypercholesterolemia, causes heart disease at a young age.

Familial hypercholesterolemia runs in Fran Tobias' family. Her father died of a heart attack in his early 40s, her mother had a heart attack at age 45, and two brothers died of heart disease. Tobias had her first heart attack at age 37, a second heart attack at age 45, a quintuple bypass surgery and eight stents.

Tobias, 56, who lives in Glen Ellyn, is successfully controlling her LDL by coming for apheresis treatments at Loyola every two weeks.

"This is literally a lifesaver for me," Tobias said. "If I were to stop, I probably would have another heart attack within 18 months to two years."

The Loyola LDL Apheresis Program is multidisciplinary. LDL apheresis is done under the guidance of medical specialists from Loyola's transfusion service, and patients have periodic clinical follow-ups with a lipidologist (cholesterol specialist). The program is directed by Binh An P. Phan, MD, and Phillip J. DeChristopher, MD, PhD. Phan is director of Loyola's Preventive Cardiology Program and DeChristopher is director of Transfusion Medicine and the Apheresis Center.

"The aim of the Loyola LDL Apheresis Program is to provide a multidisciplinary specialized service for the comprehensive evaluation and treatment of patients who require LDL apheresis," Phan said.

add to favorites email to friend print save as pdf

Related Stories

Drug OK'd for deadly genetic condition tied to cholesterol

Jan 30, 2013

(HealthDay)—Kynamro (mipomersen sodium) has been approved by the U.S. Food and Drug Administration to treat a rare inherited condition in which the body can't remove low-density lipoprotein (LDL) cholesterol from the blood.

Recommended for you

New approach to particle therapy dosimetry

Dec 19, 2014

Researchers at the National Physical Laboratory (NPL), in collaboration with EMRP partners, are working towards a universal approach to particle beam therapy dosimetry.

Supplement maker admits lying about ingredients

Dec 17, 2014

Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Shootist
1 / 5 (2) Mar 01, 2013
No unintended consequences to be had from this device, no.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.